2016/12/01 by Yi An, F. Christopher Holsinger, Zain Husain · 1 citation
Medicine · #Head and Neck Cancer Studies #Head and Neck Surgical Oncology #Salivary Gland Tumors Diagnosis and Treatment
paper · pdf · doi:10.1186/s41199-016-0016-7
openalex publication_date 2016/12/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
Current adjuvant treatment guidelines for oropharyngeal squamous cell carcinoma treated with primary surgery are based on studies that predate the human papillomavirus (HPV) era. HPV-associated oropharynx carcinoma (HPV-OPC) has a much more favorable prognosis compared to HPV-unassociated cancer and is increasingly considered to be a distinct disease entity due to its unique etiology, presentation, and behavior. Currently, there is significant interest in adjuvant treatment de-intensification of HPV-OPC patients in order to reduce treatment-related toxicity while maintaining excellent clinical outcomes. Here, we review the evidence and rationale underlying the ongoing prospective trials of adjuvant treatment de-intensification for HPV-OPC patients.